Erica Bonazzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Erica Bonazzi has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Brigida Barberio
Gastroenterology Unit, Azienda Ospedale—Università Padova, 35128 Padua, Italy
8 shared publications - Edoardo Savarino
Division of Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy
8 shared publications - Fabiana Zingone
Department of Surgery, Oncology, Gastroenterology, University of Padua, Padua, Italy
7 shared publications - Luisa Bertin
Department of Surgery, Oncology and Gastroenterology (DiSCOG), University of Padua, Via Giustiniani 2, 35128 Padua, Italy
7 shared publications - Daria Maniero
Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy
5 shared publications - Sonia Facchin
Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padua, 35128 Padua, Italy
5 shared publications
Latest Publications
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Impact of antimicrobial peptides and purified dietary fibres on human intestinal microbiota modulation : from screening to therapeutic potential and microbiota-based personalized medicine
Impact des peptides antimicrobiens et des fibres alimentaires purifiées sur le microbiote intestinal humain : du dépistage au potentiel thérapeutique et à la médecine personnalisée basée sur le microbiote: Le tractus gastro-intestinal est colonisé par une communauté de micro-organismes, appelée microbiote intestinal. La relation entre l'hôte et son microbiote est symbiotique: l'hôte fournit aux bactéries des nutriments pour se développer, tandis que les bactéries assurent le développement immunitaire, la protection contre les pathogènes et la production de nutriments et de vitamines essentiels. La composition et la fonction du microbiote intestinal peuvent être influencées par plusieurs facteurs, dont l' alimentation et la génétique. Des changements délétères dans sa composition et/ou sa fonction sont associés à des maladies, telles que les maladies inflammatoires de l'intestin (MICI). Le fait que la transplantation fécal de patients atteints de MICI à des animaux sans microbiote (axéniques) soit suffisante pour transférer la susceptibilité à la colite suggère un rôle causal joué par le microbiote intestinal dans la promotion de ces pathologies chroniques. Pour contrôler la communauté microbienne intestinale, l'hôte a plusieurs mécanismes de défense: la présence d'une couche de mucus, la sécrétion d'immunoglobulines et de peptides antimicrobiens (AMP). Les AMP sont des peptides cationiques qui neutralisent les bactéries en perméabilisant leur membrane ou en limitant leur agrégation. Chez l'homme, les principales familles sont les défensines et les cathélicidines et leur importance dans la défense de l'épithélium et des muqueuses a déjà été rapporté mais le rôle joué par le microbiote reste controversé. Au cours de ce projet de thèse, à l'aide d'un modèle in vitro du microbiote (MBRA), j'ai criblé des AMP afin de caractériser leur impact sur la composition et la fonction de divers microbiotes humains sains. J'ai ensuite étudié la capacité d'un AMP (fragment HD51-9) identifié comme étant un modulateur du potentiel pro-inflammatoire du microbiote à protéger contre la colite induite chez la souris. Les résultats obtenus soutiennent l'hypothèse selon laquelle les AMP peuvent moduler directement le microbiote en protégeant contre l'inflammation intestinale. Les fibres alimentaires sont aussi un important modulateur du microbiote. Si l'alimentation du microbiote par les fibres alimentaires fermentescibles est connue pour être un facteur de bonne santé, leur impact sur l'inflammation intestinale chronique est plus complexe. Bien que des études épidémiologiques rapportent que la consommation de régimes riches en fibres est associée à une incidence réduite des MICI, d'autres suggèrent qu'une fois la maladie établie, certains patients présentent une intolérance à ces régimes. Il a été démontré, chez la souris, qu'une supplémentation en inuline et en psyllium exacerbe ou atténue, respectivement, la colite induite, dépendamment du microbiote. Au cours de ce projet de thèse, l'impact d' inuline et psyllium sur des microbiotes humains sains a été déterminé in vitro et après transplantation dans des souris axénique. La composition et le potentiel pro-inflammatoire de certains microbiotes ont été fortement affectés (appelés "fibres sensibles"), tandis que d'autres ont été peu altérés (appelés "fibres résistants"). Uniquement la colites des souris transplantées avec des microbiotes fibres sensibles était exacerbée lorsque les souris été nourries avec un régime enrichi en inuline, et atténuée lorsqu'elles été nourries avec un régime enrichi en psyllium. Cette étude révèle l'efficacité du MBRA à identifier les microbiotes sensibles et résistants à la modulation par les fibres alimentaires, et souligne que la mesure dans laquelle ces fibres modifient la prédisposition à la colite et/ou la gravité de celle-ci est influencée par la composition du microbiote d'un individu. D'autres études sont nécessaires pour comprendre de manière mécanistique ces variabilité interindividuelle en terme de réactivité du microbiote à une exposition donnée, dans le but ultime de développer une médecine et une nutrition personnalisées basées sur le microbiote.
- 8 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Impact of antimicrobial peptides and purified dietary fibres on human intestinal microbiota modulation : from screening to therapeutic potential and microbiota-based personalized medicine
Impact des peptides antimicrobiens et des fibres alimentaires purifiées sur le microbiote intestinal humain : du dépistage au potentiel thérapeutique et à la médecine personnalisée basée sur le microbiote: Le tractus gastro-intestinal est colonisé par une communauté de micro-organismes, appelée microbiote intestinal. La relation entre l'hôte et son microbiote est symbiotique: l'hôte fournit aux bactéries des nutriments pour se développer, tandis que les bactéries assurent le développement immunitaire, la protection contre les pathogènes et la production de nutriments et de vitamines essentiels. La composition et la fonction du microbiote intestinal peuvent être influencées par plusieurs facteurs, dont l' alimentation et la génétique. Des changements délétères dans sa composition et/ou sa fonction sont associés à des maladies, telles que les maladies inflammatoires de l'intestin (MICI). Le fait que la transplantation fécal de patients atteints de MICI à des animaux sans microbiote (axéniques) soit suffisante pour transférer la susceptibilité à la colite suggère un rôle causal joué par le microbiote intestinal dans la promotion de ces pathologies chroniques. Pour contrôler la communauté microbienne intestinale, l'hôte a plusieurs mécanismes de défense: la présence d'une couche de mucus, la sécrétion d'immunoglobulines et de peptides antimicrobiens (AMP). Les AMP sont des peptides cationiques qui neutralisent les bactéries en perméabilisant leur membrane ou en limitant leur agrégation. Chez l'homme, les principales familles sont les défensines et les cathélicidines et leur importance dans la défense de l'épithélium et des muqueuses a déjà été rapporté mais le rôle joué par le microbiote reste controversé. Au cours de ce projet de thèse, à l'aide d'un modèle in vitro du microbiote (MBRA), j'ai criblé des AMP afin de caractériser leur impact sur la composition et la fonction de divers microbiotes humains sains. J'ai ensuite étudié la capacité d'un AMP (fragment HD51-9) identifié comme étant un modulateur du potentiel pro-inflammatoire du microbiote à protéger contre la colite induite chez la souris. Les résultats obtenus soutiennent l'hypothèse selon laquelle les AMP peuvent moduler directement le microbiote en protégeant contre l'inflammation intestinale. Les fibres alimentaires sont aussi un important modulateur du microbiote. Si l'alimentation du microbiote par les fibres alimentaires fermentescibles est connue pour être un facteur de bonne santé, leur impact sur l'inflammation intestinale chronique est plus complexe. Bien que des études épidémiologiques rapportent que la consommation de régimes riches en fibres est associée à une incidence réduite des MICI, d'autres suggèrent qu'une fois la maladie établie, certains patients présentent une intolérance à ces régimes. Il a été démontré, chez la souris, qu'une supplémentation en inuline et en psyllium exacerbe ou atténue, respectivement, la colite induite, dépendamment du microbiote. Au cours de ce projet de thèse, l'impact d' inuline et psyllium sur des microbiotes humains sains a été déterminé in vitro et après transplantation dans des souris axénique. La composition et le potentiel pro-inflammatoire de certains microbiotes ont été fortement affectés (appelés "fibres sensibles"), tandis que d'autres ont été peu altérés (appelés "fibres résistants"). Uniquement la colites des souris transplantées avec des microbiotes fibres sensibles était exacerbée lorsque les souris été nourries avec un régime enrichi en inuline, et atténuée lorsqu'elles été nourries avec un régime enrichi en psyllium. Cette étude révèle l'efficacité du MBRA à identifier les microbiotes sensibles et résistants à la modulation par les fibres alimentaires, et souligne que la mesure dans laquelle ces fibres modifient la prédisposition à la colite et/ou la gravité de celle-ci est influencée par la composition du microbiote d'un individu. D'autres études sont nécessaires pour comprendre de manière mécanistique ces variabilité interindividuelle en terme de réactivité du microbiote à une exposition donnée, dans le but ultime de développer une médecine et une nutrition personnalisées basées sur le microbiote.
- Open Access
Dietary Interventions and Oral Nutritional Supplementation in Inflammatory Bowel Disease: Current Evidence and Future Directions
Background: Nutritional management has become an integral part of Inflammatory Bowel Disease (IBD) care, with growing evidence supporting specific dietary interventions alongside pharmacologic therapy. However, clinical guidance remains fragmented due to heterogeneous study designs and variable endpoints. Objectives: This review critically examines the current evidence on dietary strategies and oral nutritional supplementation (ONS) in both Crohn’s Disease (CD) and Ulcerative Colitis (UC), highlighting their clinical applications, mechanisms of action, and limitations. Methods: A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science databases, analyzing studies on various dietary approaches and ONS in IBD. Results: Exclusive Enteral Nutrition (EEN) is a first-line therapy in pediatric CD, while partial enteral nutrition (PEN) and the Crohn’s Disease Exclusion Diet (CDED) show promising efficacy and better adherence in both children and adults. Whole-food-based interventions, including the Mediterranean Diet, Specific Carbohydrate Diet, plant-based diets, and emerging strategies such as CD-TREAT and the Tasty & Healthy diet, have demonstrated varying levels of benefit in disease maintenance and symptom control. Targeted exclusion diets—such as low-FODMAP, low-emulsifier, and low-sulfur diets—may relieve functional symptoms and influence inflammatory activity, although evidence remains preliminary. ONS plays a pivotal role in addressing malnutrition and improving outcomes in perioperative and hospitalized patients. Conclusions: Dietary interventions and ONS represent valuable therapeutic tools in IBD management. Future research should prioritize standardized, well-powered clinical trials and personalized nutritional approaches to better define their role within integrated care pathways.
Open AccessDietary Interventions and Oral Nutritional Supplementation in Inflammatory Bowel Disease: Current Evidence and Future Directions
Background: Nutritional management has become an integral part of Inflammatory Bowel Disease (IBD) care, with growing evidence supporting specific dietary interventions alongside pharmacologic therapy. However, clinical guidance remains fragmented due to heterogeneous study designs and variable endpoints. Objectives: This review critically examines the current evidence on dietary strategies and oral nutritional supplementation (ONS) in both Crohn’s Disease (CD) and Ulcerative Colitis (UC), highlighting their clinical applications, mechanisms of action, and limitations. Methods: A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science databases, analyzing studies on various dietary approaches and ONS in IBD. Results: Exclusive Enteral Nutrition (EEN) is a first-line therapy in pediatric CD, while partial enteral nutrition (PEN) and the Crohn’s Disease Exclusion Diet (CDED) show promising efficacy and better adherence in both children and adults. Whole-food-based interventions, including the Mediterranean Diet, Specific Carbohydrate Diet, plant-based diets, and emerging strategies such as CD-TREAT and the Tasty & Healthy diet, have demonstrated varying levels of benefit in disease maintenance and symptom control. Targeted exclusion diets—such as low-FODMAP, low-emulsifier, and low-sulfur diets—may relieve functional symptoms and influence inflammatory activity, although evidence remains preliminary. ONS plays a pivotal role in addressing malnutrition and improving outcomes in perioperative and hospitalized patients. Conclusions: Dietary interventions and ONS represent valuable therapeutic tools in IBD management. Future research should prioritize standardized, well-powered clinical trials and personalized nutritional approaches to better define their role within integrated care pathways.
- Open Access
- 16 April 2025
- Published by MDPI AG in Preprints.org
Dietary Interventions and Oral Nutritional Supplementation in Inflammatory Bowel Disease: Current Evidence and Future Directions
Background/Objectives: Inflammatory Bowel Diseases (IBD), including Crohn's Disease (CD) and Ulcerative Colitis (UC), are chronic disorders with complex pathophysiology involving immune dysregulation, gut microbiota alterations, and environmental triggers. Diet plays a critical role in disease onset and management. This review examines current evidence on dietary interventions and oral nutritional supplementation (ONS) in IBD management, assessing impacts on disease activity and clinical outcomes. Methods: A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science databases, analyzing studies on various dietary approaches and ONS in IBD. Results: Exclusive Enteral Nutrition (EEN) remains firmly established as first-line therapy for pediatric CD, achieving remission rates comparable to corticosteroids while promoting mucosal healing and avoiding steroid-related adverse effects. The Crohn's Disease Exclusion Diet with Partial Enteral Nutrition demonstrates efficacy comparable to EEN with superior long-term adherence. The Mediterranean Diet represents a sustainable anti-inflammatory approach particularly suited for maintenance therapy. Emerging evidence supports other targeted interventions including low-FODMAP diet for functional symptoms and low-emulsifier diets for active CD. ONS effectively addresses malnutrition in IBD, with formulations ranging from elemental to specialized immunomodulating products tailored to specific clinical scenarios. Conclusions: Dietary interventions and ONS are valuable components of IBD management, offering benefits for inflammation reduction and nutritional optimization. Future research should focus on personalized nutrition approaches, standardized trials, and integration with pharmacological management to enhance evidence-based recommendations for IBD patients.
- 16 April 2025
- Published by MDPI AG in Preprints.org
Open AccessDietary Interventions and Oral Nutritional Supplementation in Inflammatory Bowel Disease: Current Evidence and Future Directions
Background/Objectives: Inflammatory Bowel Diseases (IBD), including Crohn's Disease (CD) and Ulcerative Colitis (UC), are chronic disorders with complex pathophysiology involving immune dysregulation, gut microbiota alterations, and environmental triggers. Diet plays a critical role in disease onset and management. This review examines current evidence on dietary interventions and oral nutritional supplementation (ONS) in IBD management, assessing impacts on disease activity and clinical outcomes. Methods: A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science databases, analyzing studies on various dietary approaches and ONS in IBD. Results: Exclusive Enteral Nutrition (EEN) remains firmly established as first-line therapy for pediatric CD, achieving remission rates comparable to corticosteroids while promoting mucosal healing and avoiding steroid-related adverse effects. The Crohn's Disease Exclusion Diet with Partial Enteral Nutrition demonstrates efficacy comparable to EEN with superior long-term adherence. The Mediterranean Diet represents a sustainable anti-inflammatory approach particularly suited for maintenance therapy. Emerging evidence supports other targeted interventions including low-FODMAP diet for functional symptoms and low-emulsifier diets for active CD. ONS effectively addresses malnutrition in IBD, with formulations ranging from elemental to specialized immunomodulating products tailored to specific clinical scenarios. Conclusions: Dietary interventions and ONS are valuable components of IBD management, offering benefits for inflammation reduction and nutritional optimization. Future research should focus on personalized nutrition approaches, standardized trials, and integration with pharmacological management to enhance evidence-based recommendations for IBD patients.
- Open Access
Mexiletine-Induced Esophageal Ulceration: Two Case Reports and a Review of the Literature
Background and Clinical Significance: Mexiletine is a class 1B antiarrhythmic drug commonly prescribed for ventricular arrhythmias and neuropathic pain. It works as a blocker of the sodium channel that modulates cardiac conduction and reduces aberrant nerve signaling. While it is generally well tolerated, gastrointestinal side effects, such as nausea, vomiting, and abdominal pain, are relatively common. Esophagitis and esophageal ulcerations have been described as rare side effects; however, they are poorly documented in the literature. Esophageal ulceration induced by oral medications, termed pill esophagitis, occurs due to prolonged contact between the medication and the esophageal mucosa. Factors contributing to this phenomenon include improper administration, such as swallowing without sufficient water, taking medication before lying down, or inherent irritant properties of the drug itself. Mexiletine-induced esophageal ulceration has not been extensively reported, making such cases clinically significant and worth investigating. In particular, the prompt diagnosis of mexiletine-induced esophageal injury is essential for timely treatment initiation or the discontinuation of the drug, preventing complications such as bleeding, strictures, or perforation. Altogether, these actions are important to prevent the onset of potentially serious complications, such as bleeding, strictures, and the perforation of the esophagus. Case Presentation: Two different patients were included in this case report on mexiletine-induced esophageal ulceration: a 78-year-old woman affected by primary dilated cardiomyopathy and atrial fibrillation with high ventricular response and a 19-year-old man affected by dilated cardiomyopathy and systemic sclerosis. Conclusions: This case report underscores the importance of recognizing mexiletine-induced esophageal ulceration, and it advocates for timely diagnosis and management to optimize patient outcomes.
Open AccessMexiletine-Induced Esophageal Ulceration: Two Case Reports and a Review of the Literature
Background and Clinical Significance: Mexiletine is a class 1B antiarrhythmic drug commonly prescribed for ventricular arrhythmias and neuropathic pain. It works as a blocker of the sodium channel that modulates cardiac conduction and reduces aberrant nerve signaling. While it is generally well tolerated, gastrointestinal side effects, such as nausea, vomiting, and abdominal pain, are relatively common. Esophagitis and esophageal ulcerations have been described as rare side effects; however, they are poorly documented in the literature. Esophageal ulceration induced by oral medications, termed pill esophagitis, occurs due to prolonged contact between the medication and the esophageal mucosa. Factors contributing to this phenomenon include improper administration, such as swallowing without sufficient water, taking medication before lying down, or inherent irritant properties of the drug itself. Mexiletine-induced esophageal ulceration has not been extensively reported, making such cases clinically significant and worth investigating. In particular, the prompt diagnosis of mexiletine-induced esophageal injury is essential for timely treatment initiation or the discontinuation of the drug, preventing complications such as bleeding, strictures, or perforation. Altogether, these actions are important to prevent the onset of potentially serious complications, such as bleeding, strictures, and the perforation of the esophagus. Case Presentation: Two different patients were included in this case report on mexiletine-induced esophageal ulceration: a 78-year-old woman affected by primary dilated cardiomyopathy and atrial fibrillation with high ventricular response and a 19-year-old man affected by dilated cardiomyopathy and systemic sclerosis. Conclusions: This case report underscores the importance of recognizing mexiletine-induced esophageal ulceration, and it advocates for timely diagnosis and management to optimize patient outcomes.
- Open Access
- 17 December 2024
- Published by MDPI AG in Gastroenterology Insights
- Vol. 15 (4) , 1075-1092
Risk Factors and Postoperative Outcomes in Pouchitis Following Restorative Proctocolectomy: An 18-Year Single-Center Study
Background/Objectives: Restorative proctocolectomy with ileo-anal pouch anastomosis (IPAA) remains the preferred surgical treatment for ulcerative colitis (UC). However, complications like pouchitis can occur. This study aimed to describe patients who underwent IPAA for inflammatory bowel disease (IBD) at Padua Hospital from 2005 to 2023 and identify risk factors for pouchitis. Secondary objectives included evaluating the effectiveness of biological therapy in chronic antibiotic-refractory pouchitis (CARP), Crohn’s disease of the pouch (CDP), and Crohn’s-like inflammation of the pouch (CDLPI), and assessing risk factors for pouch failure. Methods: This retrospective, observational study included 109 patients whose data were collected from medical records. Univariate logistic regression was used to analyze associations between preoperative and postoperative factors and outcomes such as acute pouchitis and pouch failure. The effectiveness of biological therapy was assessed by measuring changes in the Pouchitis Disease Activity Index (PDAI) and the Modified Pouchitis Disease Activity Index (mPDAI) over a 12-month treatment period. Results: Univariate logistic regression revealed significant associations between preoperative extraintestinal manifestations (OR 3.569, 95% CI 1.240–10.720), previous diagnosis of Crohn’s disease (OR 10.675, 95% CI 1.265–90.089), and transmural inflammation at cross-sectional imaging before surgery (OR 3.453, 95% CI 1.193–9.991) with an acute pouchitis risk. Pouch failure was significantly associated with a previous diagnosis of Crohn’s disease (OR 9.500, 95% CI 1.821–49.571) and post-surgical fistulas (OR 41.597, 95% CI 4.022–430.172). Biological therapy led to a significant reduction in the PDAI score in patients with CARP, decreasing from a median of 10 to 4 (p = 0.006). Similarly, in patients with CDP or CDLPI, the mPDAI score was significantly reduced from a median of 9 to 1 (p = 0.034), with remission achieved in 5/6 (83.3%) of these patients. Conclusions: This study provides valuable insights into the management of IPAA patients and highlights the importance of early identification and treatment of risk factors for pouchitis and failure. Biological therapy demonstrated significant effectiveness in reducing disease activity in patients with CARP, CDP, and CDLPI, suggesting its role as a crucial component in managing these complications.
- 17 December 2024
- Published by MDPI AG in Gastroenterology Insights
- Vol. 15 (4) , 1075-1092
Open AccessRisk Factors and Postoperative Outcomes in Pouchitis Following Restorative Proctocolectomy: An 18-Year Single-Center Study
Background/Objectives: Restorative proctocolectomy with ileo-anal pouch anastomosis (IPAA) remains the preferred surgical treatment for ulcerative colitis (UC). However, complications like pouchitis can occur. This study aimed to describe patients who underwent IPAA for inflammatory bowel disease (IBD) at Padua Hospital from 2005 to 2023 and identify risk factors for pouchitis. Secondary objectives included evaluating the effectiveness of biological therapy in chronic antibiotic-refractory pouchitis (CARP), Crohn’s disease of the pouch (CDP), and Crohn’s-like inflammation of the pouch (CDLPI), and assessing risk factors for pouch failure. Methods: This retrospective, observational study included 109 patients whose data were collected from medical records. Univariate logistic regression was used to analyze associations between preoperative and postoperative factors and outcomes such as acute pouchitis and pouch failure. The effectiveness of biological therapy was assessed by measuring changes in the Pouchitis Disease Activity Index (PDAI) and the Modified Pouchitis Disease Activity Index (mPDAI) over a 12-month treatment period. Results: Univariate logistic regression revealed significant associations between preoperative extraintestinal manifestations (OR 3.569, 95% CI 1.240–10.720), previous diagnosis of Crohn’s disease (OR 10.675, 95% CI 1.265–90.089), and transmural inflammation at cross-sectional imaging before surgery (OR 3.453, 95% CI 1.193–9.991) with an acute pouchitis risk. Pouch failure was significantly associated with a previous diagnosis of Crohn’s disease (OR 9.500, 95% CI 1.821–49.571) and post-surgical fistulas (OR 41.597, 95% CI 4.022–430.172). Biological therapy led to a significant reduction in the PDAI score in patients with CARP, decreasing from a median of 10 to 4 (p = 0.006). Similarly, in patients with CDP or CDLPI, the mPDAI score was significantly reduced from a median of 9 to 1 (p = 0.034), with remission achieved in 5/6 (83.3%) of these patients. Conclusions: This study provides valuable insights into the management of IPAA patients and highlights the importance of early identification and treatment of risk factors for pouchitis and failure. Biological therapy demonstrated significant effectiveness in reducing disease activity in patients with CARP, CDP, and CDLPI, suggesting its role as a crucial component in managing these complications.
- Open Access
- 20 November 2024
- Published by MDPI AG in Gastroenterology Insights
- Vol. 15 (4) , 998-1013
The Esophageal Microbiota in Esophageal Health and Disease
The esophagus, traditionally viewed as a sterile conduit, is now recognized as a dynamic habitat for diverse microbial communities. The emerging evidence suggests that the esophageal microbiota plays an important role in maintaining esophageal health and contributing to disease. The aim of this systematic review was to synthesize the current knowledge on the esophageal microbiota composition, its variation between healthy individuals and those with esophageal diseases, and the potential mechanisms through which these microorganisms influence esophageal pathology. A systematic literature search was conducted using multiple databases, including PubMed, Scopus, and Web of Science, to identify relevant studies published up to July 2024. The inclusion criteria encompassed original research articles that used molecular techniques to characterize the esophageal microbiota in human subjects, comparing healthy individuals with patients affected by esophageal conditions such as gastroesophageal reflux disease (GERD), Barrett’s esophagus, eosinophilic esophagitis, and esophageal cancer. The primary outcomes were the composition and diversity of the esophageal microbiota, and the secondary outcomes included the correlations between microbial profiles and disease states. The esophageal microbiota of healthy individuals was dominated by Gram-positive bacteria, particularly Streptococcus. Conversely, the esophageal microbiota is considerably altered in disease states, with decreased microbial diversity and specific microbial signatures associated with these conditions, which may serve as biomarkers for disease progression and as targets for therapeutic intervention. However, the heterogeneous study designs, populations, and analytical methods underscore the need for standardized approaches in future research. Understanding the esophageal microbiota’s role in health and disease could guide microbiota-based diagnostics and treatments, offering novel avenues for managing esophageal conditions.
- 20 November 2024
- Published by MDPI AG in Gastroenterology Insights
- Vol. 15 (4) , 998-1013
Open AccessThe Esophageal Microbiota in Esophageal Health and Disease
The esophagus, traditionally viewed as a sterile conduit, is now recognized as a dynamic habitat for diverse microbial communities. The emerging evidence suggests that the esophageal microbiota plays an important role in maintaining esophageal health and contributing to disease. The aim of this systematic review was to synthesize the current knowledge on the esophageal microbiota composition, its variation between healthy individuals and those with esophageal diseases, and the potential mechanisms through which these microorganisms influence esophageal pathology. A systematic literature search was conducted using multiple databases, including PubMed, Scopus, and Web of Science, to identify relevant studies published up to July 2024. The inclusion criteria encompassed original research articles that used molecular techniques to characterize the esophageal microbiota in human subjects, comparing healthy individuals with patients affected by esophageal conditions such as gastroesophageal reflux disease (GERD), Barrett’s esophagus, eosinophilic esophagitis, and esophageal cancer. The primary outcomes were the composition and diversity of the esophageal microbiota, and the secondary outcomes included the correlations between microbial profiles and disease states. The esophageal microbiota of healthy individuals was dominated by Gram-positive bacteria, particularly Streptococcus. Conversely, the esophageal microbiota is considerably altered in disease states, with decreased microbial diversity and specific microbial signatures associated with these conditions, which may serve as biomarkers for disease progression and as targets for therapeutic intervention. However, the heterogeneous study designs, populations, and analytical methods underscore the need for standardized approaches in future research. Understanding the esophageal microbiota’s role in health and disease could guide microbiota-based diagnostics and treatments, offering novel avenues for managing esophageal conditions.
- Open Access
- 26 September 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (19) , 2140
Comparing Point-of-Care Technology to ELISA Testing for Infliximab and Adalimumab Levels in Adult Inflammatory Bowel Disease Patients: A Prospective Pilot Study
Introduction: Therapeutic drug monitoring (TDM) has proven to be a valuable strategy for optimizing biologic therapies, among which are anti-tumor necrosis factor (anti-TNF) treatments in inflammatory bowel disease (IBD). In particular, reactive TDM has been shown to manage treatment failures more cost-effectively than empirical dose adjustments for anti-TNF drugs. However, several challenges currently impede the widespread adoption of TDM in clinical practice, particularly addressing the delay between sample collection and result availability. To overcome this limitation, the use of point-of-care technology tests (POCTs) is a potential solution. Point-of-care technology tests are medical diagnostic tests performed at the site of patient care to provide immediate results, allowing for quicker decision-making and treatment. The current standard of care (SOC) for drug level measurement relies on the enzyme-linked immunosorbent assay (ELISA), a method that is time-consuming and requires specialized personnel. This study aims to evaluate a novel, user-friendly, and efficient POCT method (ProciseDx Inc.) and compare its performance with the SOC ELISA in assessing infliximab and adalimumab levels in blood samples from IBD patients. Methods: In this prospective, single-center study, we collected blood samples from IBD patients, both CD and UC, receiving infliximab (87 IBD patients; 50% UC and 50% CD) or adalimumab (60 patients; 14% UC and 48% CD) and we analyzed the blood’s drugs levels using both the ProciseDx Analyzer POC and the SOC ELISA. We examined the correlation between the two methods using statistical analyses, including the Deming regression test. Additionally, we assessed the ease of use, turnaround time, and overall practicality of the POCT in a clinical setting. Results: The ProciseDx test demonstrated a strong correlation with the SOC ELISA for measuring both infliximab and adalimumab levels. In particular, the overall correlation between the ProciseDx POCT and the ELISA assessments showed an r coefficient of 0.83 with an R squared value of 0.691 (95% CI 0.717–0.902) for IFX measurements, and an r coefficient of 0.85 with an R squared value of 0.739 (95% CI 0.720–0.930). Conclusions: the ProciseDx POC test offers significantly faster turnaround times and is more straightforward to use, making it a viable alternative for routine clinical monitoring. Despite its promising potential, further refinement and validation of the ProciseDx test are necessary to ensure its effectiveness across diverse patient populations and clinical settings. Future research should focus on optimizing the POC tests’ performance and evaluating its long-term impact on IBD management.
- 26 September 2024
- Published by MDPI AG in Diagnostics
- Vol. 14 (19) , 2140
Open AccessComparing Point-of-Care Technology to ELISA Testing for Infliximab and Adalimumab Levels in Adult Inflammatory Bowel Disease Patients: A Prospective Pilot Study
Introduction: Therapeutic drug monitoring (TDM) has proven to be a valuable strategy for optimizing biologic therapies, among which are anti-tumor necrosis factor (anti-TNF) treatments in inflammatory bowel disease (IBD). In particular, reactive TDM has been shown to manage treatment failures more cost-effectively than empirical dose adjustments for anti-TNF drugs. However, several challenges currently impede the widespread adoption of TDM in clinical practice, particularly addressing the delay between sample collection and result availability. To overcome this limitation, the use of point-of-care technology tests (POCTs) is a potential solution. Point-of-care technology tests are medical diagnostic tests performed at the site of patient care to provide immediate results, allowing for quicker decision-making and treatment. The current standard of care (SOC) for drug level measurement relies on the enzyme-linked immunosorbent assay (ELISA), a method that is time-consuming and requires specialized personnel. This study aims to evaluate a novel, user-friendly, and efficient POCT method (ProciseDx Inc.) and compare its performance with the SOC ELISA in assessing infliximab and adalimumab levels in blood samples from IBD patients. Methods: In this prospective, single-center study, we collected blood samples from IBD patients, both CD and UC, receiving infliximab (87 IBD patients; 50% UC and 50% CD) or adalimumab (60 patients; 14% UC and 48% CD) and we analyzed the blood’s drugs levels using both the ProciseDx Analyzer POC and the SOC ELISA. We examined the correlation between the two methods using statistical analyses, including the Deming regression test. Additionally, we assessed the ease of use, turnaround time, and overall practicality of the POCT in a clinical setting. Results: The ProciseDx test demonstrated a strong correlation with the SOC ELISA for measuring both infliximab and adalimumab levels. In particular, the overall correlation between the ProciseDx POCT and the ELISA assessments showed an r coefficient of 0.83 with an R squared value of 0.691 (95% CI 0.717–0.902) for IFX measurements, and an r coefficient of 0.85 with an R squared value of 0.739 (95% CI 0.720–0.930). Conclusions: the ProciseDx POC test offers significantly faster turnaround times and is more straightforward to use, making it a viable alternative for routine clinical monitoring. Despite its promising potential, further refinement and validation of the ProciseDx test are necessary to ensure its effectiveness across diverse patient populations and clinical settings. Future research should focus on optimizing the POC tests’ performance and evaluating its long-term impact on IBD management.
- Top Cited PapersOpen Access
Short-Chain Fatty Acids and Human Health: From Metabolic Pathways to Current Therapeutic Implications
The gastrointestinal tract is home to trillions of diverse microorganisms collectively known as the gut microbiota, which play a pivotal role in breaking down undigested foods, such as dietary fibers. Through the fermentation of these food components, short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate are produced, offering numerous health benefits to the host. The production and absorption of these SCFAs occur through various mechanisms within the human intestine, contingent upon the types of dietary fibers reaching the gut and the specific microorganisms engaged in fermentation. Medical literature extensively documents the supplementation of SCFAs, particularly butyrate, in the treatment of gastrointestinal, metabolic, cardiovascular, and gut-brain-related disorders. This review seeks to provide an overview of the dynamics involved in the production and absorption of acetate, propionate, and butyrate within the human gut. Additionally, it will focus on the pivotal roles these SCFAs play in promoting gastrointestinal and metabolic health, as well as their current therapeutic implications.
Top Cited PapersOpen AccessShort-Chain Fatty Acids and Human Health: From Metabolic Pathways to Current Therapeutic Implications
The gastrointestinal tract is home to trillions of diverse microorganisms collectively known as the gut microbiota, which play a pivotal role in breaking down undigested foods, such as dietary fibers. Through the fermentation of these food components, short-chain fatty acids (SCFAs) such as acetate, propionate, and butyrate are produced, offering numerous health benefits to the host. The production and absorption of these SCFAs occur through various mechanisms within the human intestine, contingent upon the types of dietary fibers reaching the gut and the specific microorganisms engaged in fermentation. Medical literature extensively documents the supplementation of SCFAs, particularly butyrate, in the treatment of gastrointestinal, metabolic, cardiovascular, and gut-brain-related disorders. This review seeks to provide an overview of the dynamics involved in the production and absorption of acetate, propionate, and butyrate within the human gut. Additionally, it will focus on the pivotal roles these SCFAs play in promoting gastrointestinal and metabolic health, as well as their current therapeutic implications.
- Top Cited PapersOpen Access
- 27 March 2024
- Published by MDPI AG in Preprints.org
Short-chain Fatty Acids and Human Health: from Metabolic Pathways to Current Therapeutic Implication
The gastrointestinal tract is colonized by trillions of different microorganisms, named the gut microbiota, which is key to degrade undigested food such as dietary fibers. The fermentation of these food components leads to the production of short-chain fatty acids (SCFA) acetate, propionate, and butyrate, which exploit several beneficial roles for the host’s health. Their production and absorption happen in different ways in the human intestine and depend on the type of dietary fiber reaching the gut and the microorganisms involved in the fermentation. The supplementation of SCFAs, mostly butyrate, in treating gastrointestinal, metabolic, cardiovascular, and gut-brain-related diseases has been reported in the medical literature. This review aims to give an overview of the production and absorption dynamics of acetate, propionate, and butyrate in the human gut, with a final focus on the role played by these SCFAs on gastrointestinal and metabolic health and the present therapeutic implications.
- 27 March 2024
- Published by MDPI AG in Preprints.org
Top Cited PapersOpen AccessShort-chain Fatty Acids and Human Health: from Metabolic Pathways to Current Therapeutic Implication
The gastrointestinal tract is colonized by trillions of different microorganisms, named the gut microbiota, which is key to degrade undigested food such as dietary fibers. The fermentation of these food components leads to the production of short-chain fatty acids (SCFA) acetate, propionate, and butyrate, which exploit several beneficial roles for the host’s health. Their production and absorption happen in different ways in the human intestine and depend on the type of dietary fiber reaching the gut and the microorganisms involved in the fermentation. The supplementation of SCFAs, mostly butyrate, in treating gastrointestinal, metabolic, cardiovascular, and gut-brain-related diseases has been reported in the medical literature. This review aims to give an overview of the production and absorption dynamics of acetate, propionate, and butyrate in the human gut, with a final focus on the role played by these SCFAs on gastrointestinal and metabolic health and the present therapeutic implications.